Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran. Issue 3 (1st March 2023)
- Record Type:
- Journal Article
- Title:
- Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran. Issue 3 (1st March 2023)
- Main Title:
- Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran
- Authors:
- Jamaati, Hamidreza
Karimi, Saeed
Ghorbani, Fariba
Panahi, Yunes
Hosseini‐Baharanchi, Fatemeh Sadat
Hajimoradi, Maryam
Malek, Rayka
Noorali, Sima
Mokhtari, Majid
Khoundabi, Batoul
Sadr, Makan
Mohamadnia, Abdolreza
Zahraei, Seyed Mohsen
Hashemian, Seyed MohammadReza
Dastan, Farzaneh
Mortaz, Esmaeil
Tayeri, Katayoun
Behtaj, Fatemeh
Vaezi, Hassan
Forouzanfar, Mohammad Mehdi
Shafaghi, Shadi - Abstract:
- Abstract: Various severe acute respiratory syndrome coronavirus 2 vaccines with different platforms have been administered worldwide; however, their effectiveness in critical cases of COVID‐19 has remained a concern. In this national cohort study, 24 016 intensive care unit (ICU) coronavirus disease‐2019 (COVID‐19) admissions were included from January to April 2022. The mortality and length of ICU stay were compared between the vaccinated and unvaccinated patients. A total of 9428 (39.25%) patients were unvaccinated, and 14 588 (60.75%) patients had received at least one dose of the vaccine. Compared with the unvaccinated, the first, second, and third doses of vaccine resulted in 8%, 20%, and 33% lower risk of ICU mortality in the adjusted model, with risk ratio (RR): 0.92, 95% confidence interval (CI): 0.84–1.001, RR: 0.80, 95% CI: 0.77–0.83, and RR: 0.67, 95% CI: 0.64–0.71, respectively. The mean survival time was significantly shorter in the unvaccinated versus the fully vaccinated patients (hazard ratio [HR]: 0.84, 95% CI: 0.80–0.88); p < 0.001). All vaccine platforms successfully decreased the hazard of ICU death compared with the unvaccinated group. The duration of ICU stay was significantly shorter in the fully vaccinated than in unvaccinated group (MD, −0.62, 95% CI: −0.82 to −0.42; p < 0.001). Since COVID‐19 vaccination in all doses and platforms has been able to reduce the risk of mortality and length of ICU‐stay, universal vaccination is recommended based onAbstract: Various severe acute respiratory syndrome coronavirus 2 vaccines with different platforms have been administered worldwide; however, their effectiveness in critical cases of COVID‐19 has remained a concern. In this national cohort study, 24 016 intensive care unit (ICU) coronavirus disease‐2019 (COVID‐19) admissions were included from January to April 2022. The mortality and length of ICU stay were compared between the vaccinated and unvaccinated patients. A total of 9428 (39.25%) patients were unvaccinated, and 14 588 (60.75%) patients had received at least one dose of the vaccine. Compared with the unvaccinated, the first, second, and third doses of vaccine resulted in 8%, 20%, and 33% lower risk of ICU mortality in the adjusted model, with risk ratio (RR): 0.92, 95% confidence interval (CI): 0.84–1.001, RR: 0.80, 95% CI: 0.77–0.83, and RR: 0.67, 95% CI: 0.64–0.71, respectively. The mean survival time was significantly shorter in the unvaccinated versus the fully vaccinated patients (hazard ratio [HR]: 0.84, 95% CI: 0.80–0.88); p < 0.001). All vaccine platforms successfully decreased the hazard of ICU death compared with the unvaccinated group. The duration of ICU stay was significantly shorter in the fully vaccinated than in unvaccinated group (MD, −0.62, 95% CI: −0.82 to −0.42; p < 0.001). Since COVID‐19 vaccination in all doses and platforms has been able to reduce the risk of mortality and length of ICU‐stay, universal vaccination is recommended based on vaccine availability. … (more)
- Is Part Of:
- Journal of medical virology. Volume 95:Issue 3(2023)
- Journal:
- Journal of medical virology
- Issue:
- Volume 95:Issue 3(2023)
- Issue Display:
- Volume 95, Issue 3 (2023)
- Year:
- 2023
- Volume:
- 95
- Issue:
- 3
- Issue Sort Value:
- 2023-0095-0003-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2023-03-01
- Subjects:
- comorbidity -- COVID‐19 -- ICU stay -- mortality -- SARS‐CoV‐2 -- vaccine
Virology -- Periodicals
616 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-9071 ↗
http://www.interscience.wiley.com/jpages/0146-6615 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jmv.28607 ↗
- Languages:
- English
- ISSNs:
- 0146-6615
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5017.095000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26808.xml